The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
HMRC Contemplates Implementing Regulations to Confiscate Cryptocurrency from Tax Noncompliant Businesses
hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
Transformational year with record EBITDA underlining strong operational delivery
A period of continued significant progress
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
N4 Pharma PLC’s (AIM: N4P) shares have risen by more than 7% following the biotech firm’s announcement that it has successfully completed the single loading of EGFR and BCL-2 siRNA